{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=8", "query": { "intervention": "BCAA", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 15649, "total_pages": 1565, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T12:46:13.848Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05720702", "title": "A Feasibility Trial of OCM Supplements for the Treatment of NAFLD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "NAFLD" ], "interventions": [ { "name": "homocysteine (Hcy) lowering supplements", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-06-30", "completion_date": "2024-08-23", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05720702" }, { "nct_id": "NCT05568095", "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Upper Gastrointestinal Tract Adenocarcinoma" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1040, "start_date": "2022-11-21", "completion_date": "2026-08-28", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 31, "location_summary": "Los Angeles, California • Orange, California • Santa Monica, California + 24 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05568095" }, { "nct_id": "NCT06064877", "title": "A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Head-and-neck Squamous-cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ficlatuzumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2024-01-11", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 28, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06064877" }, { "nct_id": "NCT07321912", "title": "Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "Eflornithine", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "0 Years to 50 Years" }, "enrollment_count": 406, "start_date": "2026-06-05", "completion_date": "2036-06-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 3, "location_summary": "Tampa, Florida • Portland, Oregon • Hershey, Pennsylvania", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Portland", "state": "Oregon" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07321912" }, { "nct_id": "NCT06742281", "title": "A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "CVXGA (CVXGA50)", "type": "BIOLOGICAL" }, { "name": "COMIRNATY®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CyanVac LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 432, "start_date": "2024-12-05", "completion_date": "2026-06-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 55, "location_summary": "Anniston, Alabama • Phoenix, Arizona • Chula Vista, California + 44 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "La Palma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06742281" }, { "nct_id": "NCT00583219", "title": "Botulin-A Toxin Instillations and Overactive Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Overactive Bladder", "Detrusor Instability", "Detrusor Hyperreflexia" ], "interventions": [ { "name": "Botulinum-A toxin", "type": "DRUG" }, { "name": "Dimethyl sulfoxide (DMSO)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2006-03", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00583219" }, { "nct_id": "NCT00784836", "title": "Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "BG9418 (interferon beta 1-a)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 3, "start_date": "2008-10", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2014-05-07", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 2, "location_summary": "Detroit, Michigan • Dallas, Texas", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784836" }, { "nct_id": "NCT01904136", "title": "Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia With Gene Mutations", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "de Novo Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Natural Killer Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2014-04-22", "completion_date": "2022-02-28", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01904136" }, { "nct_id": "NCT01160744", "title": "A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "IMC-1121B (ramucirumab)", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin (AUC 6)", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin (AUC 5)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2010-09", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2019-09-13", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 38, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01160744" }, { "nct_id": "NCT02400437", "title": "Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-04", "completion_date": "2019-11", "has_results": true, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-10-25T12:46:13.848Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02400437" } ] }